🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT01526681
Active, not recruiting Observational

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

NCT01526681 · tracked via the Priya Life Science UK tracker
Sponsor
Axogen Corporation
Phase
Observational
Started
2008-11
Last updated
2026-01-26

Condition(s) studied

Peripheral Nerve Injuries

Investigational drug(s) / intervention(s)

Processed Human Nerve GraftStandard Treatment, Autogenous Nerve Graft, Direct Suture, etc.Autogenous Nerve GraftNerve Tube ConduitAutologous Breast Reconstruction with NeurotizationAutologous Breast Reconstruction without Neurotization

Processed Human Nerve Graft: Implantation of appropriate length of processed human nerve graft at the time of surgery

Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.: Historical control from established literature

Autogenous Nerve Graft: Nerve gap reconstructions with autogenous nerve graft within the upper extremity

Nerve Tube Conduit: Nerve gap reconstructions with nerve tube conduit within the upper extremity

Study summary

This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Primary Study Criteria (RANGER Avance): Inclusion Criteria: * Males and Females who have undergone nerve repair using the Avance® Nerve Graft for the repair of a nerve injury * Returned for at least one post-operative follow-up visit Exclusion Criteria: • Subject who in the opinion of the investigator, have not or likely will not complete at least some portion of the investigator's recommended follow-up. Addendum 1 (MATCH) Criteria: Inclusion Criteria: * Have nerve transection injuries to the upper extremity; * Have undergone tension free end to end nerve coaptation on both the proximal and distal portion of the nerve gap with nerve autograft or nerve entubulation with nerve tube conduit at a participating ANG-CP-005 registry site after 2004 and; * Have completed sufficient follow-up assessments at a regeneration rate of 2mm/day to determine the outcomes of the repair or is willing to comply with site specific post-operative care procedures and assessments to determine the outcome of the repair. Exclusion Criteria: * Direct nerve repairs; * Nerve gaps greater than 70mm; * Subjects who, in the opinion of the investigator, were non-compliant to the investigator's post-operative treatment or rehabilitation instructions; * Any subject who at the discretion of the Investigator is not suitable for inclusion in the study. Addendum 2 (Sensation-NOW) Criteria: Inclusion Criteria: * Female ≥ 18 years old * Undergo post mastectomy autologous breast reconstruction with one type of autologous flap (no stacked reconstructions or use of implant with autologous flap) * Neurotization must be completed using a donor nerve from the flap and a recipient nerve from the chest * Complete Sensory Assessment Testing with Semmes Weinstein Monofilaments (SWMF) and the following Breast-Q Questionnaires 60 - 120 days post-reconstruction: * Breast-Q Physical Well Being of the Chest * Breast-Q Satisfaction with Breast * Breast-Q Physical Well Being of the Abdomen * Breast-Q Abnormal Breast Sensations * Breast-Q Impact of Breast Sensation on Quality of Life * Breast-Q Return of Breast Sensation * Able to provide informed consent and are willing to comply with post-operative care procedures and assessments Exclusion Criteria: * Surgical history of secondary revision surgery for partial or total flap loss * Bilateral reconstruction with non-uniform treatment (i.e. 1 reconstructed breast is non-neurotized, 1 reconstructed breast is neurotized) * Currently prescribed medication known to impact nerve regeneration or to cause peripheral neuropathy * Currently undergoing IV chemotherapy or radiation * Any subject who at the discretion of the Investigator is not suitable for inclusion in the study or is unlikely to comply with follow-up schedule Additional Eligibility criteria to Modules Module 1: Native Skin Reconstructions with and without neurotization. * Buried flap reconstructions from nipple sparing mastectomy or skin sparing mastectomy OR a breast reconstruction from a skin sparing mastectomy with exposed flap skin in the peri-areolar region. * Sensory assessments must be completed on ≥ 8 Zones of Native Skin. * Center zone measurement may be on either Native Skin or Flap Skin. * All Inner and Outer zone measurements must be on Native Skin. * De-identified photo of the breast reconstruction with 9 zones identified.

Primary outcome measure(s)

Trial sites (49)

FacilityCityRegionStatus
RANGER & MATCH: Arizona Center for Hand Surgery Phoenix Arizona
RANGER: Phoenix Children's Hospital Phoenix Arizona
RANGER & MATCH: University of California - Irvine Orange California
RANGER & MATCH: The Buncke Clinic San Francisco California
Sensation-NOW: Stanford University Stanford California
Sensation-NOW: University of Colorado School of Medicine Aurora Colorado
Sensation-NOW: George Washington University Washington D.C. District of Columbia
RANGER: University of Miami Miami Florida
RANGER & MATCH: Florida Orthopaedic Institute Tampa Florida
RANGER: Hand & Upper Extremity Center of Georgia/Children's Hospital of Atlanta Atlanta Georgia
RANGER & MATCH: University of Kansas Medical Center Kansas City Kansas
Sensation-NOW: University of Kansas Medical Center Kansas City Kansas
RANGER: University of Kentucky Lexington Kentucky
Sensation-NOW: Advanced Reconstructive Care, LLC Metairie Louisiana
RANGER: Johns Hopkins University Baltimore Maryland
Sensation-NOW: Johns Hopkins University Baltimore Maryland
RANGER: Walter Reed National Military Medical Center Bethesda Maryland
MATCH: Hennepin County Medical Center Minneapolis Minnesota
RANGER & MATCH: University of Missouri - Columbia Columbia Missouri
Sensation-NOW: University of Nebraska Medical Center Omaha Nebraska
Sensation-NOW: University of Nevada, Las Vegas Las Vegas Nevada
RANGER: Multi-Disciplinary Specialists Rutherford New Jersey
RANGER & MATCH: OrthoCarolina Research Institute, Inc. Charlotte North Carolina
RANGER: Duke University Durham North Carolina
RANGER: University of Cincinnati Cincinnati Ohio
Sensation-NOW: University of Cincinnati Cincinnati Ohio
RANGER: Cleveland Clinic Cleveland Ohio
RANGER: Ohio State University Medical Center Columbus Ohio
Sensation-NOW: Ohio State University Medical Center Columbus Ohio
Sensation-NOW: University of Pennsylvania Philadelphia Pennsylvania
Sensation-NOW: East Cooper Plastic Surgery Mt. Pleasant South Carolina
RANGER & MATCH: Campbell Clinic Germantown Tennessee
RANGER & MATCH: Vanderbilt University Nashville Tennessee
Sensation-NOW: Vanderbilt University Nashville Tennessee
Sensation-NOW: University of Texas Southwestern Medical Center Dallas Texas
RANGER: University of North Texas/John Peter Smith Hospital Fort Worth Texas
Sensation-NOW: University of North Texas/John Peter Smith Hospital Fort Worth Texas
Sensation-NOW: Baylor College of Medicine Houston Texas
Sensation-NOW: Houston-Methodist Central Houston Texas
Sensation-NOW: Houston-Methodist West/North Houston Texas

+ 9 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01526681 on ClinicalTrials.gov ↗ ← All trials in the UK